Strengthening of Management Team
PL BioScience announces Strengthening of Management Team
Appointment of Oliver Dick as new Chief Technology Officer
PL BioScience announced the strengthening of its management team with the appointment of Oliver Dick, PhD. Oliver Dick joins the team as Chief Technology Officer, a strategic position as the company scales up to meet growing global demand for its animal-free cell culture solutions. Oliver Dick is an experienced operations executive with over 30 years of experience in project and line management. His expertise lies in developing and leading operational strategies along the entire supply chain within life science, diagnostic, and biopharmaceutical organizations.
“Oliver has an extensive track record in operational excellence and brings a strategic vision as well as hands-on leadership in life sciences and biopharma manufacturing to our team. With global demand for animal-free cell culture supplements increasing, we are advancing our international growth strategy and are delighted to have him as we enter into this exciting phase,” said Dr. Hatim Hemeda, CEO of PL BioScience.
“I am very excited to join PL BioScience as CTO at a time of such dynamic growth and opportunity,” said Dr. Oliver Dick. “The company has built a strong reputation for product innovation and quality in Human Platelet Lysate and is in an excellent position to shape the market globally. I look forward to working with the highly qualified team to ensure PL BioScience’s commercial success.”
Learn more in the full announcement here.
